System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Jeffrey V Lazarus is an expert in Hepatology at Hospital Clínic de Barcelona (Spain). As of October 2026, ScienceLeadR ranks Jeffrey V Lazarus in the top 1% of experts worldwide for MASH, Hepatitis and Coronavirus Infections. Jeffrey V Lazarus has authored 575 publications, the most recent in 2026, and is an investigator in 3 clinical trials, 1 of them ongoing. SLR score: 2,535 (community average: 125). How the SLR is computed.

LeadR Profile

Jeffrey V Lazarus Hospital Clínic de Barcelona Spain
2 535 ScienceLeadR Reputation 2535

Unlock

Register Login
Network Map

Hepatology

Subspecialties: Gastroenterology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2004 - 2026
Source: PubMed

University of Barcelona

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 575

Citations

Citations: 87 576 1st author: 146 Last author: 143 Unique author: 7

Main journals

J Hepatol 81
Liver Int 27
Lancet 22
Lancet Gastroenterol Hepatol 22
Nat Rev Gastroenterol Hepatol 19

Best Journals

J Hepatol 28
Lancet 18
Nat Rev Gastroenterol Hepatol 16

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
High burden of potentially undiagnosed MASH in a general population in Sweden.
PMID 42946109 — mortality, incidence, cardiometabolic risk factors, non-alcoholic fatty liver disease, risk factors, fatty liver		Clin Gastroenterol Hepatol20260
The Madrid Declaration on metabolic dysfunction-associated steatotic liver disease (MASLD). Innovation, equity, and transformation of the health-system response to the metabolic disease challenge of the 21st century.
PMID 42929259 — liver diseases, metabolic diseases, liver		Rev Esp Enferm Dig20260
Liver fibrosis risk, missed follow-up, and inequitable specialist referral in the All of Us Research Program: a retrospective cohort study.
PMID 42920888 — research design, laboratories, fibrosis, cohort studies, documentation, liver, aged, research		Lancet Reg Health Am20260
Waiting to get sick enough.
PMID 42897347 — molecular biology		Nat Med Top journal20260
Gaps in awareness of metabolic liver disease among high-risk populations in the United States.
PMID 42900157 — liver diseases, liver, health communication, health literacy		Hepatol Commun20260

Clinical Studies 3

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 1
Phase 3 1
Phase 4 1

By status:

Completed 1
Enrolling by invitation 1
Not yet recruiting 1

By type:

Interventional 2
Observational 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 2

Main Topics

Cohort/Consortium Investigators 6

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Nutrition Intervention Combined With Resmetirom for MASH
NCT07680478 — exercise, love, life style, safety, eating, non-alcoholic fatty liver disease, telemedicine, diet, mediterranean, liver, diet, food, therapeutics, meals, carbohydrates, diet, healthy		Phase 4Not yet recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS